Here we demonstrated that IL-6 and VCAM-1 are increased in NASH patients with advanced fibrosis stages, and displayed good performance in distinguishing advanced fibrosis from milder stages. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatohepatitis.